Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of recurrent kidney stone disease based on ≥2 stone events with a minimum of 1 stone event within 5 years prior to screening~* Meets the 24 hour urine oxalate excretion requirements~* The 2 most recently analyzed kidney stones prior to randomization contained 50% or more of calcium oxalate; if only one stone analysis is available, then it must have contained 50% or more of calcium oxalate~Exclusion Criteria:~* Known history of secondary causes of elevated urinary oxalate and/or recurrent kidney stones~* Primary hyperoxaluria~* Estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m\^2 at screening~* Received an investigational agent within the last 30 days or 5 half-lives, whichever is longer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumasiran Dose 1 (Type: EXPERIMENTAL): Participants will be administered lumasiran by subcutaneous (SC) injection.
- Lumasiran Dose 2 (Type: EXPERIMENTAL): Participants will be administered lumasiran by SC injection.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be administered placebo by SC injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).